Search clinical trials for: Sirolimus for Injection (Albumin-bound)

Total 2603 results

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors

Malignant Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)

Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC (Compass-001)

Non-Small Cell Lung Cancer

China
China Medical University, China

Recruiting

Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

Gastric Carcinoma

China
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.; CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma

Esophageal Small Cell Carcinoma

China
University of Washington
Aadi Bioscience, Inc.

Active, not recruiting

Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

Advanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue Sarcoma

United States
Aadi Bioscience, Inc.

Approved for marketing

Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation

TSC1 | TSC2 | PEComa, Malignant | mTOR Pathway Abberation
Peking University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Gastric Cancer | Adenocarcinoma of Esophagogastric Junction

China
Fuzhou General Hospital

Unknown

Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC

Nasopharyngeal Carcinoma

China
Shanghai Yizhong Pharmaceutical Co., Ltd.

Recruiting

Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC).

Metastatic Breast Cancer (MBC)

China
Nanfang Hospital, Southern Medical University

Not yet recruiting

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Neoadjuvant Therapy | Esophageal Carcinoma
Peking University Third Hospital
Jilin Provincial Tumor Hospital; Affiliated Hospital of Hebei University; Hebei...

Not yet recruiting

Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.

Cervical Cancer
Liaoning Tumor Hospital & Institute

Not yet recruiting

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Non Small Cell Lung Cancer
Fujian Medical University Union Hospital

Not yet recruiting

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

Chemotherapy | Radiation Therapy

China
Guangzhou Institute of Respiratory Disease
Jiangsu HengRui Medicine Co., Ltd.; BGI-Shenzhen

Completed

Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Immunotherapy

China
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Childhood Solid Neoplasm

United States
Jiangsu HengRui Medicine Co., Ltd.

Enrolling by invitation

A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Advanced Solid Tumors

China
China Medical University, China

Unknown

Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer

Advanced Gastric Cancer

China
Peking University First Hospital
Merck Sharp & Dohme LLC

Not yet recruiting

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung Cancer

China
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

Cervical Cancer | Fertility Preservation | Radical Hysterectomy | Neoadjuvant Chemoimmunotherapy

China
Shanghai Jiao Tong University School of Medicine

Completed

Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

Oral Cancer | Induction Chemotherapy | Programmed Cell Death 1 Inhibitor | Inductive Therapy

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer

Pancreatic Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere

Advanced Solid Tumors

China
First Affiliated Hospital of Zhejiang University
Hangzhou Dihua Biotechnology Co., LTD.

Recruiting

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

Gastric Adenocarcinoma | Adenocarcinoma of Gastroesophageal Junction

China
Shanghai Yizhong Biotechnology Co., Ltd.

Unknown

Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC

Non-Small Cell Lung Cancer(NSCLC)

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer (CSAPPPCC)

Uterine Cervical Cancer

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Terminated

A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma

Pancreatic Carcinoma

China
Huazhong University of Science and Technology

Not yet recruiting

Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer (OC-01)

Ovarian Cancer
Fujian Cancer Hospital

Not yet recruiting

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Advanced Solid Tumor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

Locally Advanced Unresectable Esophageal Squamous Carcinoma

China
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Cervical Cancer | Locally Advanced Cervical Cancer | PD-L1 Negative | Neoadjuvant Chemoimmunotherapy

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

Gastric Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

Advanced Breast Cancer

China
Henan Cancer Hospital

Unknown

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Triple-negative Breast Cancer
Zhejiang Cancer Hospital
Shanghai Junshi Bioscience Co., Ltd.

Suspended

A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.

Esophageal Squamous Cell Carcinoma

China
Zhejiang Cancer Hospital

Active, not recruiting

Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fudan University
CSPC Ouyi Pharmaceutical Co., Ltd.

Unknown

Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Not yet recruiting

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Breast Cancer

China
Muhammad Furqan
Celgene Corporation

Active, not recruiting

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

Small Cell Lung Cancer (SCLC)

United States
Vivozon, Inc.

Completed

Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Gastrectomy

Post-Operative Pain

Korea, Republic of
Fudan University

Recruiting

The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer

Pancreatic Cancer | Chemotherapy Effect

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer

China
Sorrento Therapeutics, Inc.

Completed

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer (TRIBECA)

Metastatic Breast Cancer | Locally Recurrent Breast Cancer

United States, Georgia, Moldova, Republic of, Romania, Serbia, Singapore, Ukraine
Tianjin Medical University Cancer Institute and...

Recruiting

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Early Stage Non-small Cell Lung Cancer

China
Mayo Clinic
National Cancer Institute (NCI)

Completed

ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer

Breast Cancer

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Suspended

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Triple Negative Breast Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma

United States

Search clinical trials for: Sirolimus for Injection (Albumin-bound)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations